From MIF-1 to endomorphin: The Tyr-MIF-1 family of peptides

Peptides

Volumn 28, Issue 12, 2007, Pages 2411-2434

  Pan, Weihong ^a   Kastin, Abba J ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Analgesia; Antiopiate; Blood brain barrier; Depression; Endomorphin; Metabolism; Opioid; Peptide; Tyr MIF 1

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN PEPTIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; ENDOMORPHIN 1; ENDOMORPHIN 2; ENDORPHIN DERIVATIVE; ENKEPHALIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; HALOPERIDOL; IMIPRAMINE; LEVODOPA; METENKEPHALIN; MORPHINE; MU OPIATE RECEPTOR; NALOXONAZINE; NALOXONE; NETAMIFTIDE; OPIATE; PROLYLLEUCYLGLYCYLAMIDE; PSYCHOSTIMULANT AGENT; SULPIRIDE; TRICYCLIC ANTIDEPRESSANT AGENT; TYROSYLPROLYLLEUCYLGLYCYLAMIDE; TYROSYLPROLYLLYSYLGLYCYLAMIDE; TYROSYLPROLYLTRYPTOPHYLGLYCYLAMIDE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; BRAIN REGION; CELL GROWTH; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG ANTAGONISM; DRUG BINDING; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ISOLATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TRANSPORT; HUMAN; HYPOTHALAMUS; IC 50; IMMUNOMODULATION; IMMUNOREACTIVITY; LOW DRUG DOSE; NONHUMAN; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SINGLE DRUG DOSE; STEM CELL; TARDIVE DYSKINESIA; TEMPERATURE; TREATMENT OUTCOME;

ANALGESICS; ANIMALS; BINDING SITES; BLOOD-BRAIN BARRIER; DEPRESSION; DYSKINESIA, DRUG-INDUCED; HUMANS; MSH RELEASE-INHIBITING HORMONE; OLIGOPEPTIDES; PARKINSON DISEASE; RATS; RECEPTORS, OPIOID;

EID: 36148952126     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.10.006     Document Type: Review

References (297)

1. Arletti R., and Bertolini A. Influence of protease inhibitors on the antidepressant activity of oxytocin. Neuropeptides 10 (1987) 241-248
2. Asakawa A., Inui A., Momose K., Ueno N., Fujino M.A., and Kasuga M. Endomorphins have orexigenic and anxiolytic activities in mice. Neuroreport 9 (1998) 2265-2267
3. Asakawa A., Inui A., Ueno N., Fujimiya M., Fujino M.A., and Kasuga M. Endomorphin-1, an endogenous mu-opioid receptor-selective agonist, stimulates oxygen consumption in mice. Horm Metab Res 32 (2000) 51-52
4. Azuma Y., and Ohura K. Endomorphin-2 modulates productions of TNF-alpha, IL-1beta, IL-10, and IL-12, and alters functions related to innate immune of macrophages. Inflammation 26 (2002) 223-232
5. Azuma Y., Ohura K., Wang P.L., and Shinohara M. Endomorphins 1 and 2 modulate chemotaxis, phagocytosis and superoxide anion production by microglia. J Neuroimmunol 119 (2001) 51-56
6. Azuma Y., Wang P.L., Shinohara M., and Ohura K. Immunomodulation of the neutrophil respiratory burst by endomorphins 1 and 2. Immunol Lett 75 (2000) 55-59
7. Banks W.A., and Kastin A.J. A brain-to-blood carrier-mediated transport system for small, N-tyrosinated peptides. Pharmacol Biochem Behav 21 (1984) 943-946
8. Banks W.A., and Kastin A.J. Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability. Brain Res Bull 15 (1985) 287-292
9. Banks W.A., and Kastin A.J. Twenty-one hormones fail to inhibit the brain to blood transport system for Tyr-MIF-1 and the enkephalins in mice. J Pharm Pharmacol 40 (1988) 289-291
10. Banks W.A., and Kastin A.J. Opposite direction of transport across the blood-brain barrier for Tyr-MIF-1 and MIF-1: comparison with morphine. Peptides 15 (1994) 23-29
11. 2 (Tyr-W-MIF-1) is transported from the brain to the blood by peptide transport system-1. J Neurosci Res 35 (1993) 690-695
12. Banks W.A., Kastin A.J., Fischman A.J., Coy D.H., and Strauss S.L. Carrier-mediated transport of enkephalins and N-Tyr-MIF-1 across blood-brain barrier. Am J Physiol 251 (1986) E477-E482
13. Banks W.A., Kastin A.J., Harrison L.M., and Zadina J.E. Perinatal treatment of rats with opiates affects the development of the blood-brain barrier transport system PTS-1. Neurotoxicol Teratol 18 (1996) 711-715
14. Banks W.A., Kastin A.J., and Michals E.A. Tyr-MIF-1 and met-enkephalin share a saturable blood-brain barrier transport system. Peptides 8 (1987) 899-903
15. Banks W.A., Kastin A.J., Michals E.A., and Barrera C.M. Stereospecific transport of Tyr-MIF-1 across the blood-brain barrier by peptide transport system-1. Brain Res Bull 25 (1990) 589-592
16. Barbeau A. Potentiation of levodopa effect by intravenous l-prolyl-l-leucyl-glycine amide in man. Lancet 2 (1975) 683-684
17. Beckwith B.E., Sandman C.A., and Kastin A.J. Influence of 3 short chain peptides (α-MSH, MSH/ACTH 4-10, MIF- I) on dimensional attention. Pharmacol Biochem Behav 5 (1976) 17-21
18. Bell R., Vaccarino A.L., Olson R.D., Olson G.A., Nores W.L., Cambre J., et al. Tolerance and morphine-induced cross-tolerance are shown to Tyr-W-MIF-1 analgesia. Peptides 20 (1999) 971-978
19. Bhargava H.N. Effects of prolyl-leucyl-glycinamide and cyclo(leucyl-glycine) on the supersensitivity of dopamine receptors in brain induced by chronic administration of haloperidol to rats. Neuropharmacology 23 (1984) 439-444
20. Bhargava H.N. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase. Life Sci 34 (1984) 873-879
21. Bihm C.C., Williams C.L., and Burks T. Central actions of endomorphins: new endogenous opioids. Proc West Pharmacol Soc 41 (1998) 81-83
22. Bjorkman S., Castensson S., and Sievertsson H. Tripeptide analogues of melanocyte-stimulating hormone release-inhibiting hormone (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor. J Med Chem 22 (1979) 931-935
23. Bocheva A., and Dzambazova-Maximova E. Antiopioid properties of the TYR-MIF-1 family. Methods Find Exp Clin Pharmacol 26 (2004) 673-677
24. Bocheva A., and Dzambazova-Maximova E. Effects of Tyr-MIF's family of peptides on immobilization stress-induced antinociception in rats. Folia Med (Plovdiv) 46 (2004) 42-46
25. Botros M., Hallberg M., Johansson T., Zhou Q., Lindeberg G., Frandberg P.A., et al. Endomorphin-1 and endomorphin-2 differentially interact with specific binding sites for substance P (SP) aminoterminal SP1-7 in the rat spinal cord. Peptides 27 (2006) 753-759
26. Bujdoso E., Jaszberenyi M., Tomboly C., Toth G., and Telegdy G. Behavioral and neuroendocrine actions of endomorphin-2. Peptides 22 (2001) 1459-1463
27. Burbach J.P., and Lebouille J.L. Proteolytic conversion of arginine-vasopressin and oxytocin by brain synaptic membranes. Characterization of formed peptides and mechanisms of proteolysis. J Biol Chem 258 (1983) 1487-1494
28. Burbach J.P.H., Bohus B., Kovacs G., Van Nispen J., Greven H., and De Wied D. Oxytocin is a precursor of potent behaviourally active neuropeptides. Eur J Pharmacol 94 (1983) 125-131
29. Burbach J.P.H., De Kloet E., and De Wied D. Oxytocin biotransformation in the rat limbic brain: characterization of peptidase activities and significance in the formation of oxytocin fragments. Brain Res 202 (1980) 401-414
30. Caraceni T., Parati E.A., Girotti F., Celano I., Frigerio C., Cocchi D., et al. Failure of MIF-I to affect behavioral responses in patients with Parkinson's diseases under L-dopa therapy. Psychopharmacology (Berl) 63 (1979) 217-222
31. Castensson S., Sievertsson H., Lindeke B., and Sum C.Y. Studies on the inhibition of oxotremorine induced tremor by a melanocyte-stimulating hormone release-inhibiting factor, thyrotropin releasing hormone and related peptides. FEBS Lett 44 (1974) 101-105
32. Celis M., Taleisnik S., and Walter R. Regulation of formation and proposed structure of the factor inhibiting the release of melanocyte-stimulating hormone. Proc Natl Acad Sci USA 68 (1971) 1428-1433
33. Champion H.C., Bivalacqua T.J., Friedman D.E., Zadina J.E., Kastin A.J., and Kadowitz P.J. Nitric oxide release mediates vasodilator responses to endomorphin 1, but not noceptin/OFQ, in hindquarters vascular bed of the rat. Peptides 19 (1998) 1595-1602
34. Champion H.C., Bivalacqua T.J., Lambert D.G., McWilliams J.E., Zadina J.E., Kastin A.J., et al. Endomorphin 1 and 2, the endogenous μ-opioid agonists, produce biphasic changes in systemic arterial pressure in the cat. Life Sci 63 (1998) 131-136
35. Champion H.C., Bivalacqua T.J., Zadina J.E., Kastin A.J., and Kadowitz P.J. Vasodilator responses to the endomorphin peptides, but not nociceptin/OFQ, are mediated by nitric oxide release. Ann NY Acad Sci 897 (1999) 165-172
36. Champion H.C., Zadina J.E., Kastin A.J., and Hackler L. The endogenous mu-opioid receptor agonists endomorphins 1 and 2 have novel hypotensive activity in the rabbit. Biochem Biophys Res Commun 235 (1997) 567-570
37. Champion H.C., Zadina J.E., Kastin A.J., Hackler L., Ge L.-J., and Kadowitz P.J. Endomorphin 1 and 2, endogenous ligands for the μ-opioid receptor, decreases cardiac output, and total peripheral resistance in the rat. Peptides 18 (1997) 1393-1397
38. Champion H.C., Zadina J.E., Kastin A.J., and Kadowitz P.J. The endogenous-μ-opioid agonists, endomorphin 1 and 2, have vasodilator activity in the hindquarters vascular bed of the rat. Life Sci 61 (1997) PL409-PL416
39. Champion H.C., Zadina J.E., Kastin A.J., and Kadowitz P.J. Endomorphin 1 and 2 have vasodepressor activity in the anesthetized mouse. Peptides 19 (1998) 925-929
40. Chen J.C., Tao P.L., Li J.Y., Wong C.H., and Huang E.Y. Endomorphin-1 and -2 induce naloxone-precipitated withdrawal syndromes in rats. Peptides 24 (2003) 477-481
41. Chiu P., Rajakumar G., Chiu S., Johnson R.L., and Mishra R.K. Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of l-prolyl-l-leucyl-glycinamide (PLG). Peptides 6 (1985) 179-183
42. Chiu S., Paulose C.S., and Mishra R.K. Effect of l-prolyl-l-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings. Peptides 2 (1981) 105-111
43. Chiu S., Paulose C.S., and Mishra R.K. Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by l-prolyl-l-leucyl-glycinamide. Science 214 (1981) 1261-1262
44. Chiu S., Wong Y.W., Wan Y.P., Chiu P., and Mishra R.K. Are the pharmacological effects of L-prolyl-L-leucyl-glycinamide (PLG) mediated through specific receptor mechanisms?. Prog Neuropsychopharmacol Biol Psychiatry 7 (1983) 739-742
45. Chu X.P., Xu N.S., Li P., and Wang J.Q. Endomorphin-1 and endomorphin-2, endogenous ligands for the mu-opioid receptor, inhibit electrical activity of rat rostral ventrolateral medulla neurons in vitro. Neuroscience 93 (1999) 681-686
46. Costain W., Buckley A., Evans M., Mishra R., and Johnson R. Modulatory effects of PLG and its peptodimimetics on haloperidol-induced catalepsy in rats. Peptides 20 (1999) 761-767
47. Crowley T., and Hydinger M. MIF, TRH, and simian social and motor behavior. Pharmacol Biochem Behav 5 (1976) 79-87
48. Csullog E., Joo G., Toth G., Dobos I., Benedek G., and Horvath G. Antinociceptive effect of continuous intrathecal administration of endomorphin-1. Pain 94 (2001) 31-38
49. Czapla M.A., Champion H.C., Zadina J.E., Kastin A.J., Hackler L., Ge L.-J., et al. Endomorphin 1 and 2, endogenous μ-opioid agonists, decrease systemic arterial pressure in the rat. Life Sci 62 (1998) 175-179
50. Czapla M.A., Gozal D., Alea O.A., Beckerman R.C., and Zadina J.E. Differential cardiorespiratory effects of endomorphin 1, endomorphin 2, DAMGO, and morphine. Am J Respir Crit Care Med 162 (2000) 994-999
51. 2-induced ventilatory stimulation by endomorphins relative to morphine. Brain Res 1059 (2005) 159-166
52. D'Amore A., and Loizzo A. Effects of neonatal treatment with Tyr-MIF-1 and naloxone on the long-term body weight gain induced by repeated postnatal stressful stimuli. Peptides 20 (1999) 1425-1430
53. D'Amore A., Pieretti S., Palazzesi S., Pezzini G., Chiarotti F., Scorza T., et al. MIF-1 can accelerate neuromotor, EEG and behavioral development in mice. Peptides 11 (1990) 527-532
54. Dickinson S.L., and Slater P. Opiate receptor antagonism by l-prolyl-l-leucyl-glycinamide, MIF-I. Peptides 1 (1980) 293-299
55. Dickinson S.L., and Slater P. A comparison of the effects of Pro-Leu-Gly NH2 and l-leucine on tremorine-induced tremor and rigidity in rats. J Pharm Pharmacol 34 (1982) 336-337
56. Dupont A., Labrie F., Pelletier G., Puviani R., Coy D.H., Schally A.V., et al. Distribution of radioactivity in the organs of the rat and mouse after injection of l-(3H)prolyl-l-leucyl-glycinamide. J Endocrinol 64 (1975) 243-248
57. Ehrensing R.H., and Kastin A.J. Melanocyte-stimulating hormone-release inhibiting hormone as an anti-depressant: a pilot study. Arch Gen Psychiat 30 (1974) 63-65
58. Ehrensing R.H., and Kastin A.J. Dose-related biphasic effect of prolyl-leucyl-glycinamide (MIF-I) in depression. Am J Psychiatry 135 (1978) 562-566
59. Ehrensing R.H., Kastin A.J., Larson P., and Bishop G.A. Melanocyte-stimulating hormone release-inhibiting factor-I and tardive dyskinesia. Dis Nerv Syst 38 (1977) 303-307
60. Ehrensing R.H., Kastin A.J., and Michell G.F. Antagonism of morphine analgesia by prolyl-leucyl-glycinamide (MIF-1) in humans. Pharmacol Biochem Behav 21 (1984) 975-978
61. Ehrensing R.H., Kastin A.J., Wurzlow G.F., Michell G.F., and Mebane A.H. Improvement in major depression after low subcutaneous doses of MIF-1. J Affect Disord 31 (1994) 227-233
62. Ehrensing R.H., Michell G.F., and Kastin A.J. Similar antagonism of morphine analgesia by MIF-1 and naloxone in Carassius auratus. Pharmacol Biochem Behav 17 (1982) 757-761
63. 2 (Tyr-W-MIF-1). Peptides 13 (1992) 623-632
64. Erchegyi J., Zadina J.E., Qiu X.-D., Kersh D.C., Ge L.-J., Brown M.M., et al. Structure-activity relationship of analogs of the endogenous brain peptides Tyr-MIF-1 and Tyr-W-MIF-1. Pept Res 6 (1993) 31-38
65. Feighner J.P., Ehrensing R.H., Kastin A.J., Leonard B.E., Sverdlov L., Nicolau G., et al. A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression. J Affect Disord 61 (2000) 119-126
66. Feighner J.P., Ehrensing R.H., Kastin A.J., Patel A., Sverdlov L., Hlavka J., et al. Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression. Int Clin Psychopharmacol 16 (2001) 345-352
67. Feighner J.P., Sverdlov L., Nicolau G., Abajian H.B., Hlavka J., Freed J.S., et al. Clinical effectiveness of nemifitide, a novel pentapeptide antidepressant, in depressed outpatients: comparison of follow-up re-treatment with initial treatment. Int J Neuropsychopharmacol 6 (2003) 207-213
68. Fichna J., Janecka A., Piestrzeniewicz M., Costentin J., and do Rego J.C. Antidepressant-like effect of endomorphin-1 and endomorphin-2 in mice. Neuropsychopharmacology 32 (2007) 813-821
69. 125I]endomorphin-2 binding sites in the MCF7 breast cancer cell line. Peptides 26 (2005) 295-299
70. Fischer P.A., Schneider E., Jacobi P., and Maxion H. Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson's syndrome. Eur Neurol 12 (1974) 360-368
71. Fisher A., Mann A., Verma V., Thomas N., Mishra R.K., and Johnson R.L. Design and synthesis of photoaffinity-labeling ligands of the l-prolyl-l-leucylglycinamide binding site involved in the allosteric modulation of the dopamine receptor. J Med Chem 49 (2006) 307-317
72. Fukunaga H., Takahashi M., Kaneto H., and Yoshikawa M. Effects of Tyr-MIF-1 on stress-induced analgesia and the blockade of development of morphine tolerance by stress in mice. Jpn J Pharmacol 79 (1999) 231-235
73. Galina Z.H., and Kastin A.J. MIF-1 antagonizes warm-, but not cold-water stress-induced analgesia: dissociation from immobility. Peptides 6 (1985) 1109-1112
74. Galina Z.H., and Kastin A.J. Tyr-MIF-1 attenuates antinociceptive responses induced by three models of stress-analgesia. Br J Pharmacol 90 (1987) 669-674
75. Galina Z.H., and Kastin A.J. Differential activity of the endogenous antiopiate Tyr-MIF-1 after various intensities of stress. Neurosci Lett 84 (1988) 312-316
76. Gentry C.L., Egleton R.D., Gillespie T.J., Abbruscato T.J., Bechowski H.B., Hruby V., et al. The effect of halogenation on blood-brain barrier permeability of a novel peptide drug. Peptides 20 (1999) 1229-1238
77. 2-adrenoceptors. Eur J Pharmacol 298 (1996) 235-239
78. Gergen K.A., Zadina J.E., and Paul D. Analgesic effects of Tyr-W-MIF-1: a mixed mu2-opioid receptor agonist/mu1-opioid receptor antagonist. Eur J Pharmacol 316 (1996) 33-38
79. Gerstenbrand F., Poewe W., Aichner F., and Kozma C. Clinical utilization of MIF-1. In: Collu R., et al. (Ed). Central nervous system effects of hypothalamic hormones and other peptides (1979), Raven Press, New York 415
80. Gerstenbrand F., Binder H., Kozma C., Pusch S.T., and Reisner T. [Infusion therapy with mif (melanocyte inhibiting factor) in Parkinson's disease (author's transl)]. Wien Klin Wochenschr 87 (1975) 822-823
81. Glatzer N.R., Derbenev A.V., Banfield B.W., and Smith B.N. Endomorphin-1 modulates intrinsic inhibition in the dorsal vagal complex. J Neurophysiol 98 (2007) 1591-1599
82. Glatzer N.R., and Smith B.N. Modulation of synaptic transmission in the rat nucleus of the solitary tract by endomorphin-1. J Neurophysiol 93 (2005) 2530-2540
83. Goldberg I.E., Rossi G.C., Letchworth S.R., Mathis J.P., Ryan-Moro J., Leventhal L., et al. Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J Pharmacol Exp Ther 286 (1998) 1007-1013
84. Gong J., Strong J.A., Zhang S., Yue X., DeHaven R.N., Daubert J.D., et al. Endomorphins fully activate a cloned human mu opioid receptor. FEBS Lett 439 (1998) 152-156
85. Gorzalka B.B., Luck K.A., and Tanco S.A. Effects of the oxytocin fragment prolyl-leucyl-glycinamide on sexual behavior in the rat. Pharmacol Biochem Behav 38 (1991) 273-279
86. Graf M.V., Hunter C.A., and Kastin A.J. Presence of delta-sleep-inducing peptide-like material in human milk. J Clin Endocrinol Metab 59 (1984) 127-132
87. Grass S., Xu I.S., Wiesenfeld-Hallin Z., and Xu X.J. Comparison of the effect of intrathecal endomorphin-1 and endomorphin-2 on spinal cord excitability in rats. Neurosci Lett 324 (2002) 197-200
88. Hackler L., Carey M.E., and Kastin A.J. Enhanced isolation of Tyr-MIF-1 from fresh human brain cortex. Brain Res Bull 36 (1995) 109-111
89. Hackler L., Kastin A.J., Erchegyi J., and Zadina J.E. Isolation of Tyr-W-MIF-1 from bovine hypothalami. Neuropeptides 24 (1993) 159-164
90. 2). Peptides 15 (1994) 945-950
91. Hackler L., Zadina J.E., Ge L.-J., and Kastin A.J. Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex. Peptides 18 (1997) 1635-1639
92. Hagan M., and Moss D. Differential effects of Tyr-MIF-1, MIF-1, and naloxone on peptide YY-induced hyperphagia. Peptides 15 (1994) 243-245
93. Han Z., Jiang Y.H., Wan Y., Wang Y., Chang J.K., and Han J.S. Endomorphin-1 mediates 2 Hz but not 100 Hz electroacupuncture analgesia in the rat. Neurosci Lett 274 (1999) 75-78
94. Hao S., Takahata O., and Iwasaki H. Isobolographic analysis of interaction between spinal endomorphin-1, a newly isolated endogenous opioid peptide, and lidocaine in the rat formalin test. Neurosci Lett 276 (1999) 177-180
95. Hara C., and Kastin A.J. Acute administration of MIF-1 or Tyr-MIF-1 inhibits haloperidol-induced catalepsy in rats. Pharmacol Biochem Behav 24 (1986) 1785-1787
96. Harrison C., McNulty S., Smart D., Rowbotham D.J., Grandy D.K., Devi L.A., et al. The effects of endomorphin-1 and endomorphin-2 in CHO cells expressing recombinant mu-opioid receptors and SH-SY5Y cells. Br J Pharmacol 128 (1999) 472-478
97. Harrison L.M., Kastin A.J., and Zadina J.E. Differential effects of endomorphin-1, endomorphin-2, and Tyr-W-MIF-1 on activation of G-proteins in SH-SY5Y human neuroblastoma membranes. Peptides 19 (1998) 749-753
98. Harrison L.M., Kastin A.J., and Zadina J.E. Tyr-W-MIF-1 attenuates down-regulation of opiate receptors in SH-SY5Y human neuroblastoma cells. J Pharmacol Exp Ther 284 (1998) 611-617
99. Harrison L.M., Zadina J.E., Banks W.A., and Kastin A.J. Effects of neonatal treatment with Tyr-MIF-1, morphiceptin and morphine on development, tail flick, and blood-brain barrier transport. Dev Brain Res 75 (1993) 207-212
100. Hatta K., Wolterink G., and Van Ree J. Prolyl-leucyl-glycinamide, thyrotropin-releasing hormone and beta-endorphin-(10-16), like antidepressants, antagonize melatonin-induced behavioural changes in rats. Eur J Pharmacol 284 (1995) 327-330
101. Hau V.S., Huber J.D., Campos C.R., Lipkowski A.W., Misicka A., and Davis T.P. Effect of guanidino modification and proline substitution on the in vitro stability and blood-brain barrier permeability of endomorphin II. J Pharm Sci 91 (2002) 2140-2149
102. Hayashi T., Kastin A.J., Coy D.H., and Olson R.D. Tyr-MIF-l affects passive avoidance behavior but not motor activity in rats. Brain Res Bull 11 (1983) 659-662
103. 2+ channel currents in rodent NG108-15 cells overexpressing μ-opioid receptors. J Physiol 507 (1998) 71-75
104. Hlinak Z., and Krejci I. Social recognition in male rats: age differences and modulation by MIF-1 and alaptide. Physiol Res 40 (1991) 59-67
105. Horowitz D., Callahan J.F., Pelus L.M., Fukuda S., and King A.G. Inhibition of hematopoietic progenitor cell growth by Tyr-MIF, an endogenous opiate modulator, and its degradation products. Int Immunopharmacol 2 (2002) 721-730
106. Horvath A., and Kastin A.J. Isolation of tyrosine-melanocyte-stimulating hormone release-inhibiting factor 1 from bovine brain tissue. J Biol Chem 264 (1989) 2175-2179
107. 2) in human brain cortex. Int J Peptide Protein Res 36 (1990) 281-284
108. Horvath G., Szikszay M., Tomboly C., and Benedek G. Antinociceptive effects of intrathecal endomorphin-1 and -2 in rats. Life Sci 65 (1999) 2635-2641
109. Hosohata K., Burkey T.H., Alfaro-Lopez J., Varga E., Hruby V.J., Roeske W.R., et al. Endomorphin-2 and endomorphin-2 are partial agonists at the human μ-opioid receptor. Eur J Pharmacol 346 (1998) 111-114
110. Huang E.Y., Chen C.M., and Tao P.L. Supraspinal anti-allodynic and rewarding effects of endomorphins in rats. Peptides 25 (2004) 577-583
111. Hui R., Chen T., and Li Y.Q. The reciprocal connections of endomorphin 1- and endomorphin 2-containing neurons between the hypothalamus and nucleus tractus solitarii in the rat. Neuroscience 138 (2006) 171-181
112. Huidobro-Toro J.P., De Carolis A.S., and Longo V.G. Action of two hypothalamic factors (TRH, MIF) and of angiotensin II on the behavioral effects of L-DOPA and 5-hydroxytryptophan in mice. Pharmacol Biochem Behav 2 (1974) 105-109
113. Huidobro-Toro J.P., Scotti d., and Longo V.G. Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II. Pharmacol Biochem Behav 3 (1975) 235-242
114. Itil T., and Herrmann W. Effects of hormones on computer-analyzed human electroencephalogram. In: Lipton M., DiMascio A., and Killam K. (Eds). Psychopharmacology: a generation of progress (1978), Raven Press, New York 729
115. Janecka A., Kruszynski R., Fichna J., Kosson P., and Janecki T. Enzymatic degradation studies of endomorphin-2 and its analogs containing N-methylated amino acids. Peptides 27 (2006) 131-135
116. Jessop D.S. Endomorphins as agents for the treatment of chronic inflammatory disease. BioDrugs 20 (2006) 161-166
117. Jessop D.S., Major G.N., Coventry T.L., Kaye S.J., Fulford A.J., Harbuz M.S., et al. Novel opioid peptides endomorphin-1 and endomorphin-2 are present in mammalian immune tissues. J Neuroimmunol 106 (2000) 53-59
118. Jessop D. Endomorphins in the immune system: distribution and anti-inflammatory functions. The first Chinese international bioactive neuropeptide conference (2007) 23-24
119. Jiang Y., Klodesky C.M., and Chang S.L. Endomorphin-1 and endomorphin-2 induce the expression of c-FOS immunoreactivity in the rat brain. Brain Res 873 (2000) 291-296
120. 35S]GTPgammaS binding by endomorphin 1 and DAMGO in mouse brains. Peptides 19 (1998) 755-758
121. Kastin A.J. Multiple direct actions of peptides on the CNS. Brain Res Bull 50 (1999) 361-362
122. Kastin A.J., Abel D.A., Ehrensing R.H., Coy D.H., and Graf M.V. Tyr-MIF-1 and MIF-1 are active in the water wheel test for antidepressant drugs. Pharmacol Biochem Behav 21 (1984) 767-771
123. Kastin A.J., Banks W.A., Hahn K., and Zadina J.E. Extreme stability of Tyr-MIF-1 in CSF. Neurosci Lett 174 (1994) 26-28
124. Kastin A.J., and Barbeau A. Preliminary clinical studies with l-prolyl-l-leucyl-glycine amide in Parkinson's disease. Can Med Assoc J 107 (1972) 1079-1081
125. Kastin A.J., and Dickson J.C. Hypophysectomy increases Tyr-MIF-1-like immunoreactivity in rat plasma. Neuroendocrinology 45 (1987) 177-181
126. Kastin A.J., Fabre L., Banks W.A., Hackler L., and Zadina J.E. Increase in plasma Tyr-MIF-1-like immunoreactivity after hypophysectomy is robust and reversible by corticosterone. Neuropeptides 28 (1995) 65-71
127. Kastin A.J., Fabre L., Banks W.A., and Zadina J.E. Uptake, content, regulation of plasma concentration, and binding of Tyr-MIF-1 by the adrenals. Neuroendocrinology 57 (1993) 541-549
128. Kastin A.J., Fabre L., Brown M.M., and Olson R.D. Age-and sex-related changes in Tyr-MIF-1-like immunoreactivity in rat plasma. Neuroendocrinology 56 (1992) 902-906
129. Kastin A.J., Fasold M.B., Smith R.R., Horner K.A., and Zadina J.E. Saturable brain-to-blood transport of endomorphins. Exp Brain Res 139 (2001) 70-75
130. Kastin A.J., Fasold M.B., and Zadina J.E. Endomorphins, Met-Enkephalin, Tyr-MIF-1, and the P-glycoprotein efflux system. Drug Metab Disp 30 (2002) 231-234
131. Kastin A.J., Galina Z.H., Horvath A., and Olson R.D. Some principles in the peptide field. J Allergy Clin Immunol 79 (1987) 6-11
132. Kastin A.J., Giles T.D., and Dickson J.C. Immunoreactive plasma concentrations of an endogenous antiopiate are higher in spontaneously hypertensive rats than in Wistar-Kyoto rats. Hypertension 8 (1986) 198-202
133. Kastin A.J., Hahn K., Banks W.A., and Zadina J.E. Delayed degradation of Tyr-MIF-1 in neonatal rat plasma. Peptides 15 (1994) 1561-1563
134. Kastin A.J., Hahn K., Banks W.A., and Zadina J.E. Regional differences in the metabolism of Tyr-MIF-1 and Tyr-W-MIF-1 by rat brain mitochondria. Biochem Pharmacol 55 (1998) 33-36
135. Kastin A.J., Hahn K., Erchegyi J., Zadina J.E., Hackler L., Palmgren M., et al. Differential metabolism of Tyr-MIF-1 and MIF-1 in rat and human plasma. Biochem Pharmacol 47 (1994) 699-709
136. Kastin A.J., Hahn K., and Zadina J.E. Regional differences in peptide degradation by rat cerebral microvessels: a novel regulatory mechanism for communication between blood and brain. Life Sci 69 (2001) 1305-1312
137. Kastin A.J., Hahn K., Zadina J.E., Banks W.A., and Hackler L. Melanocyte-stimulating hormone release-inhibiting factor-1 (MIF-1) can be formed from Tyr-MIF-1 in brain mitochondria but not in brain homogenate. J Neurochem 64 (1995) 1855-1859
138. Kastin A.J., Honour L.C., and Coy D.H. Effects of MIF-1 and three related peptides on reserpine-induced hypothermia in mice. Pharmacol Biochem Behav 15 (1981) 983-985
139. Kastin A.J., Lawrence S.P., and Coy D.H. Radioimmunoassayable N-Tyr-MIF-1-like activity in the rat brain is increased by pinealectomy. Brain Res Bull 7 (1981) 697-702
140. Kastin A.J., Nissen C., Zadina J.E., Schally A.V., and Ehrensing R.H. Naloxone-like actions of MIF-1 do not require the presence of the pituitary. Pharmacol Biochem Behav 13 (1980) 907-912
141. Kastin A.J., Olson R.D., Ehrensing R.H., Berzas M.C., Schally A.V., and Coy D.H. MIF-1's differential actions as an opiate antagonist. Pharmacol Biochem Behav 11 (1979) 721-723
142. Kastin A.J., Olson R.D., Sandman C.A., Schally A.V., and Coy D.H. Multiple independent actions of neuropeptides on behavior. In: Martinez J.L., Jensen R.A., Messing R.B., Rigter H., and McGaugh J.L. (Eds). Endogenous peptides and learning memory processes (1981), Academic Press, New York 563-577
143. Kastin AJ, Pan W. Peptides and hormesis. Crit Rev Toxicol, in press.
144. Kastin A.J., Pearson M.A., and Banks W.A. EEG evidence that morphine and an enkephalin analog cross the blood-brain barrier. Pharmacol Biochem Behav 40 (1991) 771-774
145. Kastin A.J., Schally A.V., and Kostrzewa R.M. Possible aminergic mediation of MSH release and of the CNS effects of MSH and MIF-1. Fed Proc 39 (1980) 2931-2936
146. Kastin A.J., Schwartzenburg D., Tsui L., Miller L.G., Olson G.A., and Olson R.D. Differential effects of Tyr-MIF-1 and naloxone in two animal models involving benzodiazepine. Brain Res Bull 23 (1989) 443-446
147. Kastin A.J., Scollan E.L., Ehrensing R.H., Schally A.V., and Coy D.H. Enkephalin and other peptides reduce passiveness. Pharmacol Biochem Behav 9 (1978) 515-519
148. Kastin A.J., Stephens E., Ehrensing R.H., and Fischman A.J. Tyr-MIF-1 acts as an opiate antagonist in the tail-flick test. Pharmacol Biochem Behav 21 (1984) 937-941
149. Kastin A.J., Stephens E., Zadina J.E., Coy D.H., and Fischman A.J. Tyr-MIF-1, identified in brain tissue, and its analogs are active in two models of antinociception. Pharmacol Biochem Behav 23 (1985) 1045-1049
150. Kastin A.J., Zadina J.E., Banks W.A., and Graf M.V. Misleading concepts in the field of brain peptides. Peptides 5 (1984) 249-253
151. Katz R.J., Roth K.A., and Carroll B.J. Acute and chronic stress effects on open field activity in the rat: implications for a model of depression. Neurosci Biobehav Rev 5 (1981) 247-251
152. Kavaliers M. MIF-1 and Tyr-MIF-1 antagonize morphine and opioid but not non-opioid stress-induced analgesia in the snail, Cepaea nemoralis. Peptides 8 (1987) 1-5
153. Kavaliers M., and Hirst M. Inhibitory influences of FMRFamide and PLG on stress-induced opioid analgesia and activity. Brain Res 372 (1986) 370-374
154. Kavaliers M., and Hirst M. Inhibitory influences of MIF-1 (PLG) and Tyr-MIF-1 (YPLG) on aggression and defeat-induced analgesia in mice. Peptides 7 (1986) 1007-1010
155. Kavaliers M., and Hirst M. Prolyl-leucyl-glycinamide (PLG): inhibition of offensive aggression in mice. Life Sci 39 (1986) 1729-1735
156. Kavaliers M., and Innes D.G.L. Sex differences in the effects of Tyr-MIF-1 on morphine- and stress-induced analgesia. Peptides 13 (1992) 1295-1297
157. Kavaliers M., and Innes D.G.L. Sex differences in naloxone- and Tyr-MIF-1-induced hypoalgesia. Peptides 14 (1993) 1001-1004
158. Khalil Z., Sanderson K., Modig M., and Nyberg F. Modulation of peripheral inflammation by locally administered endomorphin-1. Inflamm Res 48 (1999) 550-556
159. King M., Su W., Chang A., Zukerman A., and Pasternak G.W. Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat Neurosci 4 (2001) 268-274
160. Koek W., and Slangen J.L. Habituation of the head-poke response: effects of an amphetamine-barbiturate mixture, PLG, and fenfluramine. Psychopharmacology 72 (1981) 251-256
161. Kosson P., Bonney I., Carr D.B., and Lipkowski A.W. Endomorphins interact with tachykinin receptors. Peptides 26 (2005) 1667-1669
162. Kostowski W., Danysz W., Dyr W., Jankowska E., Krzascik P., Palejko W., et al. MIF-1 potentiates the action of tricyclic antidepressants in an animal model of depression. Peptides 12 (1991) 915-918
163. Kostrzewa R.M., and Kastin A.J. Tyr-MIF-1 attenuates development of tolerance to spiperone-induced catalepsy in rats. Brain Res Bull 31 (1993) 707-712
164. Kostrzewa R.M., White T.G., Zadina J.E., and Kastin A.J. MIF-1 attenuates apomorphine stereotypies in adult rats after neonatal 6-hydroxydopamine. Eur J Pharmacol 163 (1989) 33-42
165. 2 in rats. Pharmacol Biochem Behav 31 (1989) 833-837
166. Koyuncuoglu H., Berkman K., and Sabuncu H. Feeding, drinking, urine osmolality in DI brattleboro rats: changes by morphine, naloxone, d-amino acids, prolyl-leucyl-glycinamide (PLG). Pharmacol Biochem Behav 20 (1984) 29-33
167. Krause W., Nieber K., Ehrlich A., Bienert M., and Oehme P. Naloxone-like protective effect of MIF-1 (Pro-Leu-Gly-NH2) on hemorrhagic shock. Pharmazie 39 (1984) 352-353
168. Kruse H. Neuropharmacological studies with thyrotropin releasing hormone (TRH) and other hypothalamic hormones. Naunyn Schmiedebergs Arch Pharmacol 297 Suppl 1 (1977) S61-S62
169. Labuz D., Berger S., Mousa S.A., Zollner C., Rittner H.L., Shaqura M.A., et al. Peripheral antinociceptive effects of exogenous and immune cell-derived endomorphins in prolonged inflammatory pain. J Neurosci 26 (2006) 4350-4358
170. Levy M.I., DeNigris Y., and Davis K.L. Rapid antidepressant activity of melanocyte-inhibiting factor: a clinical trial. Biol Psychiatry 17 (1982) 259-263
171. Lin X., Xue L.Y., Wang R., Zhao Q.Y., and Chen Q. Protective effects of endomorphins, endogenous opioid peptides in the brain, on human low density lipoprotein oxidation. FEBS J 273 (2006) 1275-1284
172. Lin X., Yang D.J., Cai W.Q., Zhao Q.Y., Gao Y.F., Chen Q., et al. Endomorphins, endogenous opioid peptides, provide antioxidant defense in the brain against free radical-induced damage. Biochim Biophys Acta 1639 (2003) 195-202
173. Lipa S.M., Kavaliers M., and Ossenkopp K.P. Differential inhibitory effects of MIF-1, Tyr-MIF-1, naloxone and β-funaltrexamine on body rotation-induced analgesia in the meadow vole, Microtus pennsylvanicus. Peptides 10 (1989) 493-497
174. Lisi T.L., and Sluka K.A. A new electrochemical HPLC method for analysis of enkephalins and endomorphins. J Neurosci Methods 150 (2006) 74-79
175. Liu J., Yu Y., Fan Y.Z., Chang H., Liu H.M., Cui Y., et al. Cardiovascular effects of endomorphins in alloxan-induced diabetic rats. Peptides 26 (2005) 607-614
176. Luciano M.G., Zadina J.E., Kastin A.J., and Coy D.H. Mu and delta opiate receptors in rat brain are affected by GTP but not by MIF-1. Brain Res Bull 7 (1981) 677-682
177. Malin D.R., Zadina J.E., Lake J.R., Rogillio R.B., Benson T.M., Corriere L.S., et al. Tyr-MIF-1 precipitates abstinence syndrome in morphine-dependent rats. Brain Res 610 (1993) 169-171
178. Marcotte E.R., Chugh A., Mishra R.K., and Johnson R.L. Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1). Peptides 19 (1998) 403-406
179. Maresh G.A., Kastin A.J., Brown T.T., Zadina J.E., and Banks W.A. Peptide transport system 1 (PTS-1) for Tyr-MIF-1 and Met-enkephalin differs from the receptors for either. Brain Res 839 (1999) 336-340
180. Martin-Schild S., Gerall A.E., Kastin A.J., and Zadina J.E. Endomorphin-2 is an endogenous opioid in primary sensory afferent fibers. Peptides 19 (1998) 1783-1789
181. Martin-Schild S., Gerall A.E., Kastin A.J., and Zadina J.E. Differential distribution of endomorphin 1- and endomorphin 2-like immunoreactivities in the CNS of the rodent. J Comp Neurol 405 (1999) 450-471
182. Martin-Schild S., Zadina J.E., Gerall A.E., Vigh S., and Kastin A.J. Localization of endomorphin-2-like immunoreactivity in the rat medulla and spinal cord. Peptides 18 (1997) 1641-1649
183. McDougall J.J., Baker C.L., and Hermann P.M. Attenuation of knee joint inflammation by peripherally administered endomorphin-1. J Mol Neurosci 22 (2004) 125-137
184. 2+ channel inhibition by endomorphins via the cloned mu-opioid receptor expressed in NG108-15 cells. Eur J Pharmacol 340 (1997) R1-R2
185. Mizoguchi H., Narita M., Oji D.E., Suganuma C., Nagase H., Sora I., et al. The mu-opioid receptor gene-dose dependent reductions in G-protein activation in the pons/medulla and antinociception induced by endomorphins in mu-opioid receptor knockout mice. Neuroscience 94 (1999) 203-207
186. Mizoguchi H., Narita M., Wu H., Narita M., Suzuki T., Nagase H., et al. Differential involvement of mu(1)-opioid receptors in endomorphin- and beta-endorphin-induced G-protein activation in the mouse pons/medulla. Neuroscience 100 (2000) 835-839
187. Mokrushin A., and Emelyanov N. Effects of melanostatine (MIF-1) on focal potentials in slices of rat brain cortex. Neuropeptides 20 (1991) 87-94
188. Montgomery S.A., Feighner J.P., Sverdlov L., Shrivastava R.K., Cunningham L.A., Kiev A., et al. Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder. Int J Neuropsychopharmacol 9 (2006) 517-528
189. Mousa S.A., Machelska H., Schafer M., and Stein C. Immunohistochemical localization of endomorphin-1 and endomorphin-2 in immune cells and spinal cord in a model of inflammatory pain. J Neuroimmunol 126 (2002) 5-15
190. Mycroft F.J., Bhargava H.N., and Wei E.T. Pharmacological activities of the MIF-1 analogues Pro-Leu-Gly, Tyr-Pro-Leu-Gly and pareptide. Peptides 8 (1987) 1051-1055
191. 2 and pareptide inhibit development of tolerance to haloperidol catalepsy in the mouse. Peptides 5 (1984) 883-887
192. Nair R.M.G., Kastin A.J., and Schally A.V. Isolation and structure of hypothalamic MSH release-inhibiting hormone. Biochem Biophys Res Commun 43 (1971) 1376-1425
193. Nakayama D., Watanabe C., Watanabe H., Mizoguchi H., Sakurada T., and Sakurada S. A Tyr-W-MIF-1 analog containing D-Pro2 discriminates among antinociception in mice mediated by different classes of mu-opioid receptors. Eur J Pharmacol 563 (2007) 109-116
194. Narita M., Mizoguchi H., Narita M., Dun N.J., Hwang B.H., Endoh T., et al. G protein activation by endomorphins in the mouse periaqueductal gray matter. J Biomed Sci 7 (2000) 221-225
195. 35S]GTPgammaS binding in the mouse spinal cord. Eur J Pharmacol 351 (1998) 383-387
196. Narita M., Ozaki S., Ioka M., Mizoguchi H., Nagase H., Tseng L.F., et al. Lack of the involvement of mu1-opioid receptor subtype on motivational effects induced by the endogenous mu-opioid receptor ligands endomorphin-1 and -2 in the mouse. Neurosci Lett 308 (2001) 17-20
197. Narita M., Ozaki S., and Suzuki T. Endomorphin-induced motivational effect: differential mechanism of endomorphin-1 and endomorphin-2. Jpn J Pharmacol 89 (2002) 224-228
198. Nicolau G., Feighner J.P., Stout R., Hlavka J., Gutierrez M., Ciric S., et al. Comparison of systemic exposure to nemifitide following two methods of subcutaneous administration to healthy volunteers. Biopharm Drug Dispos 26 (2005) 379-385
199. Niesink R.J., and van Ree J.M. Neuropeptides and social behavior of rats tested in dyadic encounters. Neuropeptides 4 (1984) 483-496
200. Nomura S., Shimizu J., Kinjo M., Kametani H., and Nakazawa T. A new behavioral test for antidepressant drugs. Eur J Pharmacol 83 (1982) 171-175
201. Nores W.L., Olson R.D., Olson G.A., Vaccarino A.L., Bell R.L., Zadina J.E., et al. Tyr-W-MIF-1-induced conditioned place preference. Peptides 20 (1999) 479-484
202. Olson R.D., Kastin A.J., Olson G.A., King B.M., Von Almen T.K., Berzas M.C., et al. MIF-I suppresses deprivation-induced fluid consumption in rats. Peptides 1 (1980) 353-357
203. Ott M.C., Costain W.J., Mishra R.K., and Johnson R.L. l-Prolyl-l-leucyl-glycinamide and its peptidomimetic analog 3(R)-[(2(S)-pyrrolidylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) attenuate haloperidol-induced c-fos expression in the striatum. Peptides 21 (2000) 301-308
204. Patel H.J., Venkatesan P., Halfpenny J., Yacoub M.H., Fox A., Barnes P.J., et al. Modulation of acetylcholine release from parasympathetic nerves innervating guinea-pig and human trachea by endomorphin-1 and -2. Eur J Pharmacol 374 (1999) 21-24
205. Petersson M., and Unvas-Moberg K. Prolyl-leucyl-glycinamide shares some effects with oxytocin but decreases oxytocin levels. Physiol Behav 83 (2004) 475-481
206. Pierce T.L., Grahek M.D., and Wessendorf M.W. Immunoreactivity for endomorphin-2 occurs in primary afferents in rats and monkeys. Neuroreport 9 (1998) 385-389
207. Pierce T.L., and Wessendorf M.W. Immunocytochemical mapping of endomorphin-2-immunoreactivity in rat brain. J Chem Neuroanat 18 (2000) 181-207
208. Pignatiello M.F., Olson G.A., Kastin A.J., Ehrensing R.H., McLean J.H., and Olson R.D. MIF-1 is active in a chronic stress animal model of depression. Pharmacol Biochem Behav 32 (1989) 737-742
209. Plotnikoff N.P., and Kastin A.J. Oxotremorine antagonism by prolyl-leucyl-glycine amide administered by different routes and with several anticholinergics. Pharmacol Biochem Behav 2 (1974) 417-419
210. Plotnikoff N.P., and Kastin A.J. Pharmacological studies with a tripeptide, prolyl-leucyl-glycinamide. Arch Int Pharm Therap 211 (1974) 211-224
211. Plotnikoff N.P., Kastin A.J., Anderson M.S., and Schally A.V. DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF). Life Sci 10 (1971) 1279-1283
212. Plotnikoff N.P., Kastin A.J., Anderson M.S., and Schally A.V. Oxotremorine antagonism by a hypothalamic hormone, melanocyte-stimulating hormone release-inhibiting factor. MIF Proc Soc Exp Biol Med 140 (1972) 811-814
213. Plotnikoff N.P., Kastin A.J., Anderson M.S., and Schally A.V. Deserpidine antagonism by a tripeptide, l-prolyl-l-leucylglycinamide. Neuorendocrinology 11 (1973) 67-71
214. Plotnikoff N.P., Minard F.N., and Kastin A.J. DOPA potentiation in ablated animals and brain levels of biogenic amines in intact animals after prolyl-leucylglycinamide. Neuroendocrinology 14 (1974) 271-279
215. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
216. Pretorius H.T., Kastin A.J., and Banks W.A. Binding of Tyr-MIF-1 to isolated brain capillaries. Brain Res Bull 17 (1986) 829-831
217. Przewlocka B., Mika J., Labuz D., Toth G., and Przewlocki R. Spinal analgesic action of endomorphins in acute, inflammatory and neuropathic pain in rats. Eur J Pharmacol 367 (1999) 189-196
218. Pucilowski O., Plaznik A., and Kostowski W. MIF-1 facilitates passive avoidance retention. Pol J Pharmacol Pharm 34 (1982) 107-113
219. Pulvirenti L., and Kastin A.J. Blockade of brain dopamine receptors antagonizes the anti-immobility effect of MIF-1 and Tyr-MIF-1 in rats. Eur J Pharmacol 151 (1988) 289-292
220. Pulvirenti L., and Kastin A.J. MIF-1 reduces stress-induced eating in rats. New Trends Exp Clin Psychiat 4 (1988) 229-233
221. Pulvirenti L., and Kastin A.J. Naloxone, but not Tyr-MIF-1, reduces volitional ethanol drinking in rats: correlation with degree of spontaneous preference. Pharmacol Biochem Behav 31 (1988) 129-134
222. Rajakumar G., Naas F., Johnson R.L., Chiu S., Yu K.L., and Mishra R.K. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of l-prolyl-l-leucyl-glycinamide (PLG). Peptides 8 (1987) 855-861
223. Redding T.W., Kastin A.J., Gonzalez-Barcena D., Coy D.H., Hirotsu Y., Ruelas J., et al. The disappearance, excretion, and metabolism of tritiated prolyl-leucyl-glycinamide in man. Neuroendocrinology 16 (1974) 119-126
224. 3H-labeled l-prolyl-l-leucyl-glycinamide in the rat. Neuroendocrinology 11 (1973) 92-100
225. Renlund S., Erlandsson I., Hellman U., Silberring J., Wernstedt C., Lindstrom L., et al. Micropurification and amino acid sequence of beta-casomorphin-8 in milk from a woman with postpartum psychosis. Peptides 14 (1993) 1125-1132
226. 3H]-Tyr-Pro: a possible biosynthetic route for endomorphins. Regul Pept 134 (2006) 54-60
227. Sakurada S., and Sakurada T. Endomorphins as endogenous peptides for mu-opioid receptor: their differences in the pharmacological and physiological characters. In: Kastin A.J. (Ed). Handbook of biologically active peptides (2006), Elsevier, Burlington, MA 1333-1338
228. Sakurada S., Hayashi T., Yuhki M., Fujimura T., Murayama K., Yonezawa A., et al. Differential antagonism of endomorphin-1 and endomorphin-2 supraspinal antinociception by naloxonazine and 3-methylnaltrexone. Peptides 23 (2002) 895-901
229. Sakurada S., Hayashi T., Yuhki M., Orito T., Zadina J.E., Kastin A.J., et al. Differential antinociceptive effects induced by intrathecally administered endomorphin-1 and endomorphin-2 in the mouse. Eur J Pharmacol 427 (2001) 203-210
230. Sakurada S., Hayashi T., Yuki M., Fujimura T., Murayama K., Yonezawa A., et al. Differential antagonism of endomorphin-1 and endomorphin-2 spinal antinociception by naloxonazine and 3-methoxynaltrexone. Brain Res 881 (2000) 1-8
231. Sakurada S., Zadina J.E., Kastin A.J., Katsuyama S., Fujimura T., Murayama K., et al. Differential involvement of μ-opioid receptor subtypes in endomorphin-1- and -2-induced antinociception. Eur J Pharmacol 372 (1999) 25-30
232. Sander G., Kastin A.J., and Giles T.D. MIF-1 does not act like naloxone in antagonizing the cardiovascular activity of leucine-enkephalin in the conscious dog. Pharmacol Biochem Behav 17 (1982) 1301-1303
233. Sapru H.N., and Chitravanshi V.C. Responses to microinjections of endomorphin and nociceptin into the medullary cardiovascular areas. Clin Exp Pharmacol Physiol 29 (2002) 243-247
234. Sartania N., Behyhe S., Magyar A., Ronai A., Medzihradszky K., and Borsodi A. Opioid binding profile of morphiceptin. Tyr-MIF-1 and dynorphin-related peptides in rat brain membranes. Neuropeptides 30 (1996) 225-230
235. Schally A.V., and Kastin A.J. Purification of a bovine hypothalamic factor which elevates pituitary MSH levels in rats. Endocrinology 79 (1966) 768-772
236. Schneider E., Fischer P.A., Jacobi P., and Reh W. [The influence of MIF (melanocyte-stimulating hormone-release inhibiting factor) on psychomotor function and mood in parkinsonian patients. Preliminary report (author's transl)]. Arzneimittelforschung 28 (1978) 1296-1297
237. Schreff M., Schulz S., Wiborny D., and Hollt V. Immunofluorescent identification of endomorphin-2-containing nerve fibers and terminals in the rat brain and spinal cord. Neuroreport 9 (1998) 1031-1034
238. Scimonelli T., and Celis M.E. Inhibition by l-prolyl-l-leucyl-glycinamide (PLG) of alpha-melanocyte stimulating hormone release from hypothalamic slices. Peptides 3 (1982) 885-889
239. Seale J.V., Jessop D.S., and Harbuz M.S. Immunohistochemical staining of endomorphin 1 and 2 in the immune cells of the spleen. Peptides 25 (2004) 91-94
240. Shane R., Wilk S., and Bodnar R.J. Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. Brain Res 815 (1999) 278-286
241. Sharma S., Paladino P., Gabriele J., Saeedi H., Henry P., Chang M., et al. Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: a model of human tardive dyskinesia. Peptides 24 (2003) 313-319
242. 2 (PLG; MIF-1). Life Sci 40 (1987) 2007-2010
243. 35S]GTPgammaS binding in rat brain: evidence for partial agonist activity at mu-opioid receptors. J Neurochem 70 (1998) 1567-1576
244. Smith R.R., Martin-Schild S., Kastin A.J., and Zadina J.E. Decreases in endomorphin-2-like immunoreactivity concomitant with chronic pain after nerve injury. Neuroscience 105 (2001) 773-778
245. Soignier R.D., Vaccarino A.L., Brennan A.M., Kastin A.J., and Zadina J.E. Analgesic effects of endomorphin-1 and endomorphin-2 in the formalin test in mice. Life Sci 67 (2000) 907-912
246. Somogyvari-Vigh A., Kastin A.J., Liao J., Zadina J.E., and Pan W. Endomorphins exit the brain by a saturable efflux system at the basolateral surface of cerebral endothelial cells. Exp Brain Res 156 (2004) 224-230
247. Stone L.S., Fairbanks C.A., Laughlin T.M., Nguyen H.O., Bushy T.M., Wessendorf M.W., et al. Spinal analgesic actions of the new endogenous opioid peptides endomorphin-1 and -2. Neuroreport 8 (1997) 3131-3135
248. Storr M., Gaffal E., Schusdziarra V., and Allescher H.D. Endomorphins 1 and 2 reduce relaxant non-adrenergic, non-cholinergic neurotransmission in rat gastric fundus. Life Sci 71 (2002) 383-389
249. Stratton L.O., and Kastin A.J. Increased acquisition of a complex appetitive task after MSH and MIF. Pharmacol Biochem Behav 3 (1975) 901-904
250. Straub R., Wolff C., Fassold A., Hofbauer R., Chover-Gonzales A., Richards L., et al. Anti-inflammatory role of endomorphins in osteoarthritis, rheumatoid arthritis, and adjuvant arthritis. Rheumatol Arthritis (2007)
251. Sugimoto-Watanabe A., Kubota K., Fujibayashi K., and Saito K. Antinociceptive effect and enzymatic degradation of endomorphin-1 in newborn rat spinal cord. Jpn J Pharmacol 81 (1999) 264-270
252. Sun R.Q., Wang Y., Zhao C.S., Chang J.K., and Han J.S. Changes in brain content of nociceptin/orphanin FQ and endomorphin 2 in a rat model of neuropathic pain. Neurosci Lett 311 (2001) 13-16
253. Teskey G.C., and Kavaliers M. Prolyl-leucyl-glycinamide reduces aggression and blocks defeat-induced opioid analgesia in mice. Peptides 6 (1985) 165-167
254. Tomboly C., Peter A., and Toth G. In vitro quantitative study of the degradation of endomorphins. Peptides 23 (2002) 1573-1580
255. Tseng L.F., Narita M., Suganuma C., Mizoguchi H., Ohsawa M., Nagase H., et al. Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse. J Pharmacol Exp Ther 292 (2000) 576-583
256. Ukai M., Katoh T., and Mamiya T. Endomorphin-1 improves scopolamine-induced impairment of short-term memory via mu1-opioid receptor in mice. Neuroreport 12 (2001) 3723-3727
257. Ukai M., and Lin H.P. Endomorphins 1 and 2 induce amnesia via selective modulation of dopamine receptors in mice. Eur J Pharmacol 446 (2002) 97-101
258. Ukai M., and Okuda A. Endomorphin-1, an endogenous mu-opioid receptor agonist, improves apomorphine-induced impairment of prepulse inhibition in mice. Peptides 24 (2003) 741-744
259. Ukai M., Watanabe Y., and Kameyama T. Effects of endomorphins-1 and -2, endogenous mu-opioid receptor agonists, on spontaneous alternation performance in mice. Eur J Pharmacol 395 (2000) 211-215
260. van der Velde C.D. Rapid clinical effectiveness of MIF-I in the treatment of major depressive illness. Peptides 4 (1983) 297-300
261. Versteeg D. Neurohypophyseal hormones and brain neurochemistry. Pharmacol Ther 19 (1983) 297-325
262. Viard E., and Sapru H.N. Endomorphin-2 in the medial NTS attenuates the responses to baroreflex activation. Brain Res 1073-1074 (2006) 365-373
263. Voith K., and Synthetic. MIF analogues. Part II. Dopa potentiation and fluphenazine antagonism. Arzneimittelforschung 27 (1977) 2290-2293
264. Walter R., Griffiths E., and Hooper K. Production of MSH-release-inhibiting hormone by a particulate preparation of hypothalami: mechanisms of oxytocin inactivation. Brain Res 60 (1973) 449-457
265. Walter R., Hoffman P.L., Flexner J., and Flexner L. Neurohypophyseal hormones, analogs, and fragments: their effect on puromycin-induced amnesia. Proc Natl Acad Sci USA 72 (1975) 4180-4184
266. Walter R., Neidle A., and Marks N. Significant differences in the degradation of pro-leu-gly-nH2 by human serum and that of other species. Proc Soc Exp Biol Med 148 (1975) 98-103
267. Wang Q.P., Zadina J.E., Guan J.-L., Kastin A.J., Funahashi H., and Shioda S. Endomorphin-2 immunoreactivity in the cervical dorsal horn of the rat spinal cord at the electron microscopic level. Neuroscience 113 (2002) 593-605
268. Wang Q.P., Zadina J.E., Guan J.-L., Kastin A.J., and Shioda S. Electron microscopic examination of the endomorphin 2-like immunoreactive neurons in the rat hypothalamus. Brain Res 969 (2003) 126-134
269. Watanabe H., Nakayama D., Yuhki M., Sawai T., Sakurada W., Katsuyama S., et al. Differential inhibitory effects of mu-opioids on substance P- and capsaicin-induced nociceptive behavior in mice. Peptides 27 (2006) 760-768
270. Watanabe H., Nakayama D., Ito K., Watanabe C., Mizoguchi H., Fujimura T., et al. A Tyr-W-MIF-1 analog containing D-Pro2 acts as a selective mu2-opioid receptor antagonist in the mouse. J Pharmacol Exp Ther 312 (2005) 1075-1081
271. Wiebe J.P., and Kavaliers M. Analgesic effects of the putative FSH-suppressing gonadal steroid, 3 alpha-hydroxy-4-pregnen-20-one: possible modes of action. Brain Res 461 (1988) 150-157
272. Williams C.A., Wu S.Y., Dun S.L., Kwok E.H., and Dun N.J. Release of endomorphin-2 like substances from the rat spinal cord. Neurosci Lett 273 (1999) 25-28
273. Wilson A.M., Soignier R.D., Zadina J.E., Kastin A.J., Nores W.L., Olson R.D., et al. Dissociation of analgesic and rewarding effects of endomorphin-1 in rats. Peptides 21 (2000) 1871-1874
274. Yamaguchi T., Kitagawa K., and Kuraishi Y. Itch-associated response and antinociception induced by intracisternal endomorphins in mice. Jpn J Pharmacol 78 (1998) 337-343
275. Yang Y., and Chiu T. Opioid and antiopioid actions of Tyr-MIF-1, Tyr-W-MIF-1 and hemorphin-4 on rat locus coeruleus neurons: intracellular recording in vitro. Chin J Physiol 40 (1997) 131-135
276. Yehuda S., and Kastin A.J. Interaction of MIF-I or α-MSH with d-amphetamine or chlorpromazine on thermoregulation and motor activity of rats maintained at different ambient temperatures. Peptides 1 (1980) 243-248
277. Yehuda S., Kastin A.J., and Coy D.H. Antagonistic actions of MIF-1 on the hypothermia and hypomotility induced by β-endorphin or morphine. Int J Neurosci 11 (1980) 317-320
278. Yu Y., Cui Y., Wang X., Fan Y.Z., Liu J., Yan X., et al. Endomorphin1 and endomorphin2, endogenous potent inhibitors of electrical field stimulation (EFS)-induced cholinergic contractions of rat isolated bronchus. Peptides 27 (2006) 1846-1851
279. Yu Y., Shao X., Wang C.L., Liu H.M., Cui Y., Fan Y.Z., et al. In vitro and in vivo characterization of opioid activities of endomorphins analogs with novel constrained C-terminus: evidence for the important role of proper spatial disposition of the third aromatic ring. Peptides 28 (2007) 859-870
280. Yu Y., Wang X., Cui Y., Fan Y.Z., Liu J., and Wang R. Abnormal modulation of cholinergic neurotransmission by endomorphin 1 and endomorphin 2 in isolated bronchus of type 1 diabetic rats. Peptides 27 (2006) 2770-2777
281. Zadina J.E., Chang S.L., Ge L.-J., and Kastin A.J. Mu opiate receptor down-regulation by morphine and up-regulation by nolaxone in SH-SY5Y human neuroblastoma cells. J Pharmacol Exp Ther 265 (1993) 254-265
282. Zadina J.E., Hackler L., Ge L.-J., and Kastin A.J. A potent and selective endogenous agonist for the μ-opiate receptor. Nature 386 (1997) 499-502
283. Zadina J.E., and Kastin A.J. Interactions between the antiopiate Tyr-MIF-1 and the mu opiate morphiceptin at their respective binding sites in brain. Peptides 6 (1985) 965-970
284. Zadina J.E., and Kastin A.J. Interactions of Tyr-MIF-1 at opiate receptor sites. Pharmacol Biochem Behav 25 (1986) 1303-1305
285. Zadina J.E., Kastin A.J., Ge L.J., Gulden H., and Bungart K.J. Chronic, but not acute, administration of morphine alters antiopiate (Tyr-MIF-1) binding sites in rat brain. Life Sci 44 (1989) 555-561
286. A/benzodiazepine receptor. Neurosci Lett 110 (1990) 143-147
287. Zadina J.E., Kastin A.J., Ge L.-J., and Brantl V. Hemorphins, cytochrophins, and human β-casomorphins bind to antiopiate (Tyr-MIF-1) as well as opiate binding sites in rat brain. Life Sci 47 (1990) PL25-PL30
288. Zadina J.E., Kastin A.J., Ge L.-J., and Hackler L. Mu, delta, and kappa opiate receptor binding of Tyr-MIF-1 and of Tyr-W-MIF-1, its active fragments, and two potent analogs. Life Sci 55 (1994) PL461-PL466
289. 2). Neurosci Lett 155 (1993) 220-222
290. Zadina J.E., Kastin A.J., Kersh D., and Wyatt A. Tyr-MIF-1 and hemorphin can act as opiate agonists as well as antagonists in the guinea pig ileum. Life Sci 51 (1992) 869-885
291. 2) in rat brain. Pharmacol Biochem Behav 17 (1982) 1193-1198
292. Zadina J.E., Kastin A.J., Manasco P.K., Pignatiello M.F., and Nastiuk K.L. Long-term hyperalgesia by neonatal β-endorphin and morphiceptin is blocked by neonatal Tyr-MIF-1. Brain Res 409 (1987) 10-18
293. 2 opiate receptors. Neurosci Lett 215 (1996) 65-69
294. Zamfirova R., Bocheva A., Dobrinova Y., and Todorov S. Study on the antinociceptive action of Tyr-K-MIF-1, a peptide from the MIF family. Auton Autacoid Pharmacol 27 (2007) 93-98
295. Zanardo V., Nicolussi S., Carlo G., Marzari F., Faggian D., Favaro F., et al. Beta endorphin concentrations in human milk. J Pediatr Gastroenterol Nutr 33 (2001) 160-164
296. Zetler G. Cholecystokinin octapeptide (CCK-8), ceruletide and analogues of ceruletide: effects on tremors induced by oxotremorine, harmine and ibogaine. A comparison with prolyl-leucylglycine amide (MIF), anti-Parkinsonian drugs and clonazepam. Neuropharmacology 22 (1983) 757-766
297. Zhang X.-Y., Zadina J.E., Ehrlich M., and Kastin A.J. Tyr-MIF-1, but not MIF-1 or morphine, decreases cyclic AMP-dependent protein kinase activity extracted from HeLa cells. Mol Cell Neurosci 3 (1992) 348-353